Article
Pharmacology & Pharmacy
Cormac Kennedy, Amelia Smith, Stephen Doran, Michael Barry
Summary: This study evaluated the utilization of Entresto in Ireland and found that patients prescribed Entresto were older and more symptomatic compared to those in the PARADIGM-HF trial. Despite the increase in Entresto utilization in Ireland, the expenditure in the first year was substantially lower than predicted. Additionally, the initiation of Entresto was associated with a reduction in the use of other medications for heart failure.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Review
Pharmacology & Pharmacy
Nor Hidayah Mustafa, Juriyati Jalil, Satirah Zainalabidin, Mohammed S. M. Saleh, Ahmad Yusof Asmadi, Yusof Kamisah
Summary: Cardiovascular diseases are a significant clinical burden worldwide, and heart failure is a common disease resulting from uncontrolled hypertension. Sacubitril/valsartan, a new drug combination, has been approved for patients with heart failure, but its molecular mechanism of action in cardiac remodeling is still unclear.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Dany Jaffuel, Erika Nogue, Philippe Berdague, Michel Galinier, Pauline Fournier, Marion Dupuis, Frederic Georger, Marie-Pierre Cadars, Jean-Etienne Ricci, Nathalie Plouvier, Francois Picard, Vincent Puel, Jean-Pierre Mallet, Carey M. Suehs, Nicolas Molinari, Arnaud Bourdin, Francois Roubille
Summary: Optimizing medical cardiac treatment for sleep apnoea in patients with chronic heart failure and reduced ejection fraction is recommended. The impact of sacubitril-valsartan on sleep apnoea remains unknown. Results suggest a significant decrease in AHI after 3 months of SV treatment, supporting the current guidelines for HFrEF optimization and indicating potential positive airway pressure sparing effects.
Article
Cardiac & Cardiovascular Systems
Massimo Volpe, Johann Bauersachs, Antoni Bayes-Genis, Javed Butler, Alain Cohen-Solal, Giovanna Gallo, Andrea Simone Deichl, Muhammad Shahzeb Khan, Allegra Battistoni, Burkert Pieske, Yoshihiko Saito, Shelley Zieroth
Summary: Current international guidelines recommend switching ACE-i or ARBs to sacubitril/valsartan (S/V) in stable outpatients affected by heart failure with reduced ejection fraction (HFrEF) who remain symptomatic despite being on optimal medical therapy. New data may support further clinical applications and benefits of S/V beyond ambulatory HFrEF patients, possibly also in HFmrEF patients. Additional clinical trial data are required to confirm the potential benefits of S/V in patients with mid-range or preserved EF, or in combination with sodium-glucose co-transporter 2 inhibitors or in post-myocardial infarction HF.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Maura Brioschi, Yuri D'Alessandra, Massimo Mapelli, Irene Mattavelli, Elisabetta Salvioni, Sonia Eligini, Alice Mallia, Veronica Ricci, Erica Gianazza, Stefania Ghilardi, Piergiuseppe Agostoni, Cristina Banfi
Summary: Sacubitril/Valsartan, a combination drug for heart failure treatment, reduces the levels of miR-29b-3p, miR-221-3p, and miR-503-5p in the plasma of patients with stable HF. These miRNAs have potential roles in HFrEF pathophysiology.
Review
Cardiac & Cardiovascular Systems
Kazuhiko Kido, Bailey M. Colvin, Thomas W. Szymanski, Maya Guglin
Summary: This review provides an overview of off-label indications for Sacubitril/valsartan to assist clinicians in assessing its appropriateness in specific patient populations.
JOURNAL OF CARDIAC FAILURE
(2022)
Article
Chemistry, Multidisciplinary
Tabrez R. Shaikh, Christy P. George, Priyanka Bhukya, Nikita Shelke, Komal Pawar, Abhijit Garai, Rambabu Dandela, Rajesh G. Gonnade, Ashwini K. Nangia
Summary: Entresto is a salt-cocrystal supramolecular complex used for treating chronic heart failure. It exhibits different crystalline forms, with Form-I and Form-III demonstrating higher stability and lower hygroscopicity.
Article
Spectroscopy
Bahia Abbas Moussa, Hanaa M. A. Hashem, Marianne Alphonse Mahrouse, Sally Tarek Mahmoud
Summary: A sensitive and accurate spectrofluorimetric method has been proposed for the simultaneous determination of Sacubitril calcium and Valsartan in a binary mixture. The method utilizes native fluorescence and a first derivative ratio method to eliminate spectral interference, showing no significant difference when compared with a reported method. It is linear in the concentration range of 100-1000 ng/ml for both compounds and can be used for quantitative determination in pure and pharmaceutical dosage forms.
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
(2021)
Article
Cardiac & Cardiovascular Systems
Jawad H. Butt, Pooja Dewan, Pardeep S. Jhund, Inder S. Anand, Dan Atar, Junbo Ge, Akshay S. Desai, Luis E. Echeverria, Lars Kober, Carolyn S. P. Lam, Aldo P. Maggioni, Felipe Martinez, Milton Packer, Jean L. Rouleau, David Sim, Dirk J. Van Veldhuisen, Bojan Vrtovec, Faiez Zannad, Michael R. Zile, Jianjian Gong, Martin P. Lefkowitz, Adel R. Rizkala, Scott D. Solomon, John J. McMurray
Summary: This study investigated the efficacy of sacubitril/valsartan in heart failure patients according to their frailty status. The results showed that frail patients had a higher risk and worse outcomes compared to nonfrail patients. Sacubitril/valsartan seemed to have a greater reduction in the primary endpoint with increasing frailty, indicating that frail patients may derive more benefits from this treatment.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2022)
Article
Pharmacology & Pharmacy
Tianyang Hu, Yiting Liu, Yake Lou
Summary: This study evaluated the cost-effectiveness of early or late initiation of Sacubitril-valsartan compared to enalapril in patients with acute decompensated heart failure (ADHF). The results showed that early initiation of Sacubitril-valsartan after stabilization from ADHF is highly cost-effective, while late initiation is still cost-effective but not as much as early initiation.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Yahe Xu, Mingjie Zhang, Yijun Chen, Xi Chen, Wenting Song, Limin Zhu, Liping Liu, Xiaolei Gong, Yuqi Zhang, Zhuoming Xu
Summary: Sacubitril/valsartan may be effective in pediatric HF patients, but its safety and clinical outcomes may vary depending on the etiology and anatomy of HF.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Giuseppe Vergaro, Paolo Sciarrone, Concetta Prontera, Silvia Masotti, Veronica Musetti, Alessandro Valleggi, Alberto Giannoni, Michele Senni, Michele Emdin, Claudio Passino
Summary: Clinical trials and observational cohorts have shown that circulating renin levels can predict the reduction in NT-proBNP levels in patients with heart failure and reduced ejection fraction after initiation of sacubitril/valsartan. Renin assessment may be useful in identifying potential responders who can benefit more from the treatment.
Review
Medicine, General & Internal
Moiud Mohyeldin, Lorena B. Tavares, Mustafa Boorenie, Deya Abureesh, Saman Ejaz, Lubna Durrani, Safeera Khan
Summary: This systematic review evaluates the safety and efficacy of using sacubitril/valsartan in acute decompensated heart failure. The findings suggest that it is an effective measure for patients with ADHF and cardiogenic shock, with overall good safety outcomes but some reports of serious adverse events recommending cautious use.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2021)
Review
Endocrinology & Metabolism
Marina Nikolic, Jovana Novakovic, Galina Ramenskaya, Vladimir Kokorekin, Nevena Jeremic, Vladimir Jakovljevic
Summary: Cold exposure and sacubitril/valsartan treatment have significant effects on the function and metabolism of brown adipose tissue (BAT). Further research should focus on exploring the synergistic effects of sacubitril/valsartan treatment in low temperature environmental conditions.
DIABETOLOGY & METABOLIC SYNDROME
(2022)
Article
Cardiac & Cardiovascular Systems
Safia Chatur, Brian L. Claggett, Finnian R. McCausland, Jean Rouleau, Michael R. Zile, Milton Packer, Marc A. Pfeffer, Martin Lefkowitz, John J. V. McMurray, Scott D. Solomon, Muthiah Vaduganathan
Summary: An investigation found that moderate estimated glomerular filtration rate decline when transitioning from RASi to sacubitril/valsartan is not consistently associated with adverse outcomes, and its long-term benefits are retained across a broad range of eGFR declines in heart failure patients.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)